Heart attacks are often considered the leading cause of death among people in the United States. While most often individuals having heart disease or having experienced a heart attack are treated through changes in lifestyle, others are now looking to oral chelation therapy. In this type of treatment, a compound known as EDTA, a man-made solution is infused into the body.
EDTA used in this therapy has not as of yet been approved by the United States Food and Drug Administration or FDA. Still, approximately there were over 110,000 adults in the United States opting for this method of treatment in a study completed in 2007. Ultimately, chelation provides a chemical process which uses a substance to bind molecules such as minerals and metals to hold the molecules tightly in place.
The therapy, originally used to eliminate excess and toxic metals and waste from the body is nothing new. For, EDTA has also been used in some Western medical practices with regards to lead poisoning and reducing iron overloads. However, when used to treat heart conditions, a health care provider must carefully inject a solution which includes disodium EDTA, an amino acid which is man made into the veins. Most often, individuals must receive more than thirty of these injections on a weekly basis until the treatment moves to a maintenance phase.
To determine whether or not this type of therapy may be helpful, the National Heart, Lung and Blood Institute along with the National Center for Complementary and Integrative Health or NCCIH sponsored a trial to examine the success rate of chelation therapy on individuals whom had a previous history of heart attacks. Ultimately, the trial showed that the infusions provided a modest reduction in cardiovascular events. Whereas, further examination showed that the treatment only benefited cardiovascular patients with a history of diabetes.
As only 1/3 of the participants were known to have diabetes, the results varied. However, in most cases, these individuals showed a 41 percent drop in cardiovascular events, a 40% risk of death due to coronary events, stroke and non-fatal heart attacks. Participants in this group also showed a 52% percent drop in repetitive heart attacks and a 43% drop in deaths from non-related causes. Whereas, most individuals whom did not have diabetes reported no significant benefits from having received the infusions.
The trial also looked at people taking high dosages of mineral and vitamin supplements in addition to the injections. In most cases, the results showed that the supplements along with the injections reduced the risk of heart attacks in the chelation therapy group versus participants whom were only given placebos.
During the trial, sixteen percent of individuals receiving the chelation therapy and fifteen percent receiving placebos ceased the injections due to adverse reactions. In four cases, the events were serious. Whereas, there was one death in each the chelation therapy group and the placebo group. To date, the main side of effect related to EDTA remains a burning sensation when the solution is placed in the vein.
As with almost all medical studies, more research is needed before a final determination as to the success of the therapy can be made. For, these reports are from the first study ever conducted. As such, the information provided through the study does not provide enough detail to support the infusions as being a safe or effective treatment for heart attack victims.
EDTA used in this therapy has not as of yet been approved by the United States Food and Drug Administration or FDA. Still, approximately there were over 110,000 adults in the United States opting for this method of treatment in a study completed in 2007. Ultimately, chelation provides a chemical process which uses a substance to bind molecules such as minerals and metals to hold the molecules tightly in place.
The therapy, originally used to eliminate excess and toxic metals and waste from the body is nothing new. For, EDTA has also been used in some Western medical practices with regards to lead poisoning and reducing iron overloads. However, when used to treat heart conditions, a health care provider must carefully inject a solution which includes disodium EDTA, an amino acid which is man made into the veins. Most often, individuals must receive more than thirty of these injections on a weekly basis until the treatment moves to a maintenance phase.
To determine whether or not this type of therapy may be helpful, the National Heart, Lung and Blood Institute along with the National Center for Complementary and Integrative Health or NCCIH sponsored a trial to examine the success rate of chelation therapy on individuals whom had a previous history of heart attacks. Ultimately, the trial showed that the infusions provided a modest reduction in cardiovascular events. Whereas, further examination showed that the treatment only benefited cardiovascular patients with a history of diabetes.
As only 1/3 of the participants were known to have diabetes, the results varied. However, in most cases, these individuals showed a 41 percent drop in cardiovascular events, a 40% risk of death due to coronary events, stroke and non-fatal heart attacks. Participants in this group also showed a 52% percent drop in repetitive heart attacks and a 43% drop in deaths from non-related causes. Whereas, most individuals whom did not have diabetes reported no significant benefits from having received the infusions.
The trial also looked at people taking high dosages of mineral and vitamin supplements in addition to the injections. In most cases, the results showed that the supplements along with the injections reduced the risk of heart attacks in the chelation therapy group versus participants whom were only given placebos.
During the trial, sixteen percent of individuals receiving the chelation therapy and fifteen percent receiving placebos ceased the injections due to adverse reactions. In four cases, the events were serious. Whereas, there was one death in each the chelation therapy group and the placebo group. To date, the main side of effect related to EDTA remains a burning sensation when the solution is placed in the vein.
As with almost all medical studies, more research is needed before a final determination as to the success of the therapy can be made. For, these reports are from the first study ever conducted. As such, the information provided through the study does not provide enough detail to support the infusions as being a safe or effective treatment for heart attack victims.
About the Author:
When you are looking for information about oral chelation, come to our web pages today. More details are available at http://www.heartdrop.com now.
I was diagnosed as HEPATITIS B carrier in 2013 with fibrosis of the
ReplyDeleteliver already present. I started on antiviral medications which
reduced the viral load initially. After a couple of years the virus
became resistant. I started on HEPATITIS B Herbal treatment from
ULTIMATE LIFE CLINIC (www.ultimatelifeclinic.com) in March, 2020. Their
treatment totally reversed the virus. I did another blood test after
the 6 months long treatment and tested negative to the virus. Amazing
treatment! This treatment is a breakthrough for all HBV carriers..